Last reviewed · How we verify
NCT06768515: DONOR-OBS
ICU Management of Brain-Dead Donors Before Multi-Organ Procurement and Factors Associated With the Number of Organs Retrieved
trial testing No interventtion in Death, Brain in 1,000 participants. Currently enrolling.
15 February 2026
Quick facts
| Lead sponsor | Société Française d'Anesthésie et de Réanimation |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 23 April 2025 |
| Primary completion | 15 February 2026 |
| Estimated completion | 15 February 2026 |
| Sites | 2 locations across France |
Drugs / interventions tested
- No interventtion
Conditions studied
- Death, Brain — all drugs for Death, Brain →
Sponsor
Société Française d'Anesthésie et de Réanimation
Who can join
18 and older, any sex, with Death, Brain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Solid organ transplantation is the treatment of choice for end stage organ failure to improve patients' quality of life and survival. Each year, more than 5,000 solid organ transplants are performed in France, mainly from brain death donors (BDD). Approximately 1,500 BDD donors have one or more organs removed each year. Despite the growing demand for transplanted organs, the number of organs available from deceased donors has remained stable over the past few decades. This highlights the need to optimize the management of potential BDD, in order to increase both the quality and number of transplanted organs. Several studies have found an association between the characteristics and management of BDD donors and the number of organs, or even the function of transplanted organs. Data suggest that hemodynamic, respiratory, and metabolic therapeutic targets during BDD management prior to multi-organ procurement were associated with a higher number of transplanted organs compared to standard care. However, this has never been confirmed in a French population. Furthermore, while the impact of these therapeutic goals has been studied after the donor is in a state of brain death, the events occurring in the ICU before reaching brain death status and their impact on the number of organs retrieved have not been investigated. Lastly, the intensity of the therapeutic interventions used to achieve these goals, and certain management delays, have only been partially studied. Our hypothesis is that achieving a bundle of therapeutic goals, and the intensity of the interventions used to reach these goals, both before and after BDD, are associated with a greater number of organs retrieved.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06768515
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Death, Brain
Currently open trials in the same condition.
- NCT06308952 — Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation · Phase 4 · recruiting
Other Société Française d'Anesthésie et de Réanimation trials
Trials by the same sponsor.
- NCT07526220 — Prognostic Factors in Critically Ill Patients Admitted After Caustic Ingestion in France · not yet recruiting
- NCT07317635 — Impact of Implementing a National Classification of Surgical Emergencies on Postoperative Morbidity and Mortality: a Pro · not yet recruiting
- NCT07182916 — Factors Associated With Early Readmission in Critical Care · recruiting
- NCT06257407 — Perioperative Hemostasis Management in Liver Transplantation · recruiting
- NCT06487442 — Management of Postoperative Pain in France: a Prospective National Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06768515 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Société Française d'Anesthésie et de Réanimation
- Last refreshed: 16 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06768515.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing